Abstract
The aim of the study. The aim of the work was to investigate in vivo anticancer activity of cis- and trans-diadamanthylcarboxylates of dirhenium(III) alone and together with cisplatin in form of nanobins.Materials and methods. Model of tumor growth, Guerin’s carcinoma; intraperitoneal administration of cisplatin, dirhenium(III) compounds in liposomes and of binary liposomes, containing both cytostatics; volumes and final weights of tumors were measured.Results. In vivo antitumor properties of two dirhenium(III) dicarboxylates with 1-adamantanecarboxylic acid moieties as ligands with cis- (I) and trans- (II) orientation of the carboxylic groups around a cluster fragment alone and together with cisplatin were presented; an attempt to understand differences in a possible mechanism of anticancer activity of the substances were undertaken. Antiradical and DNA-binding properties of I and II were the matter of consideration.Conclusions. Cis- and trans- compounds of dirhenium I and II had close antitumor activity in vivo with a little bit superiority of the cis- analog. Mechanisms of anticancer activity of I and II are different and may also include monofunctional adduct formation and subsequent interstrand cross-linking for the II substance, formation of protein-DNA cross-links, etc.
Highlights
Anticancer activity in vivo of cis-dicarboxylates of dirhenium(III) including cis-diadamantate alone and together with cisplatin was first presented in 2008 [1]
The aim and objectives of the study The aim of the work was to investigate in vivo anticancer activity of cis- and trans-diadamanthylcarboxylates of dirhenium(III) alone and together with cisplatin in form of nanobins
Introductions of I and II in liposomes led to the significant effects of tumor inhibition (Fig. 2)
Summary
Anticancer activity in vivo of cis-dicarboxylates of dirhenium(III) including cis-diadamantate alone and together with cisplatin was first presented in 2008 [1]. Binuclear clusters of dirhenium(III) with an unique quadruple metal–metal bond have their own anticancer activity and being introduced together with cisplatin in molar ratio 1: 4, that was called by us the “rhenium-platinum antitumor system” (Re-Pt system), is an example of the successful combinational therapy, leading to interruption of the tumor growth, see review [1]. Dirhenium(III) compounds possessed antiradical, antihemolytic, antioxidant, nephro- and hepatoprotective properties that reduced or even almost eradicated the toxic properties of cisplatin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
